Enzyme replacement therapy in the mouse model of Pompe disease
Nina Raben(APT Therapeutics (United States)), Paul H. Plötz(National Institutes of Health), Abigail L. Gilbert(National Institute of Arthritis and Musculoskeletal and Skin Diseases), Billy S. Collins, Beth L. Thurberg(Sanofi (United States)), S DWIVEDI(National Institute of Arthritis and Musculoskeletal and Skin Diseases), Robert J. Mattaliano, M. J. Danon(Hennepin County Medical Center), Kanneboyina Nagaraju(Children's National)
Cited by 215
Related Papers
2. Classification and Diagnosis of Diabetes:<i>Standards of Care in Diabetes—2023</i>
|Diabetes Care|2022|2.4k
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
|Diabetes Care|2022|1.9k
Therapy of Lupus Nephritis
|New England Journal of Medicine|1986|1.2k
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
|Diabetologia|2022|986
A New Approach to the Classification of Idiopathic Inflammatory Myopathy
|Medicine|1991|974